论文部分内容阅读
目的探讨同步放化疗治疗乳腺癌锁骨上淋巴结转移的临床疗效。方法将180例乳腺癌术后出现锁骨上淋巴结转移的患者随机分为同步放化疗组和单纯化疗组,分别给予同步放化疗治疗及单纯化疗。结果同步放化疗组和单纯化疗组的有效率分别为85.6%和65.6%,2组比较差异有统计学意义(χ2=4.164,P=0.032)。同步放化疗组和单纯化疗组2年生存率为63.3%和41.1%(χ2=5.164,P=0.029),2组的2年生存率比较差异有统计学意义。治疗后1年局部复发率差异有统计学意义。同步放化疗组恶心、呕吐及白细胞下降、贫血及血小板下降的发生率与单纯化疗组比较,差异无统计学意义。结论同步放化疗可提高乳癌锁骨上淋巴结转移患者的近期疗效和远期生存率,不良反应与单纯化疗相近。
Objective To investigate the clinical efficacy of concurrent chemoradiotherapy in the treatment of supraclavicular lymph node metastasis of breast cancer. Methods A total of 180 patients with supraclavicular lymph node metastasis after breast cancer surgery were randomly divided into concurrent chemoradiotherapy group and chemotherapy alone group, and were given concurrent chemoradiotherapy and chemotherapy alone. Results The effective rates of concurrent chemoradiotherapy and chemotherapy alone were 85.6% and 65.6%, respectively. There was significant difference between the two groups (χ2 = 4.164, P = 0.032). The 2-year survival rates of concurrent chemoradiation and chemotherapy alone were 63.3% and 41.1%, respectively (χ2 = 5.164, P = 0.029). There was significant difference in 2-year survival between the two groups. One year after treatment, the local recurrence rate had statistical significance. The incidence of nausea, vomiting and leukopenia, anemia and thrombocytopenia in concurrent chemoradiotherapy group were not statistically different from those in chemotherapy alone group. Conclusions Simultaneous chemoradiotherapy can improve the short-term and long-term survival of patients with supraclavicular lymph node metastasis of breast cancer. The adverse reaction is similar to that of chemotherapy alone.